HEALIOS
Healios aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected with retinal degenerative diseases.The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine.
HEALIOS
Industry:
Biotechnology Health Care Medical
Founded:
2011-02-24
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.healios.co.jp
Total Employee:
11+
Status:
Active
Contact:
81 3 3544 8730
Email Addresses:
[email protected]
Total Funding:
3.02 B JPY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics WordPress Google Universal Analytics Euro ReCAPTCHA ReCAPTCHA V2 Pound Sterling Japanese Yen
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Dainippon Sumitomo Pharma
Dainippon Sumitomo Pharma investment in Venture Round - Healios
Shibuya Kogyo
Shibuya Kogyo investment in Venture Round - Healios
Nikon
Nikon investment in Venture Round - Healios
Shin Nippon Biomedical Laboratories (SNBL)
Shin Nippon Biomedical Laboratories (SNBL) investment in Venture Round - Healios
Healios Investment
Healios Investment investment in Venture Round - Healios
tella
tella investment in Venture Round - Healios
Dogan
Dogan investment in Venture Round - Healios
Astem
Astem investment in Corporate Round - Healios
iPS Academia Japan
iPS Academia Japan investment in Corporate Round - Healios
Nomura
Nomura investment in Corporate Round - Healios
Official Site Inspections
http://www.healios.co.jp Semrush global rank: 2.65 M Semrush visits lastest month: 6.41 K
- Host name: 150.60.159.39
- IP address: 150.60.159.39
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Healios"
Company Overview - Healios K.K.
Tokyo Office. Address Hibiya Mitsui Tower 12F, WORK STYLING, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006, Japan. GoogleMapSee details»
Healios K.K.
Presentation of the research results of Healios’ eNK cells and UDCs at the 22nd Congress of the Japanese Society for Regenerative Medicine (March 23-25) 2019.09.30. TOPICS. Healios to Present at 2019 Cell & Gene Meeting on the …See details»
Company History - Healios K.K.
JP; EN; Mission & Vision; Regenerative Medicine; ... Company History. Company History. February 2011. Retina Institute Japan, K.K. (currently HEALIOS K.K.) was established in …See details»
Healios - Crunchbase Company Profile & Funding
Oct 8, 2013 Healios closed its last funding round on Oct 8, 2013 from a Venture - Series Unknown round. Who are Healios 's competitors? Alternatives and possible competitors to Healios may include Illumina , NuChem Sciences , …See details»
Healios Co. - Crunchbase Company Profile & Funding
Healios Co. is a biotechnology company that develops regeneration and cellular medicines. Tokyo, Tokyo, Japan; 51-100; Private; www.healios.co.jp ; 1,258,616See details»
Healios KK - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 www.healios.co.jp. Public Company | 2011 | Tokyo-to, Japan | 50-100 | TYO: 4593 | www.healios.co.jp. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
Healios K.K. (TYO: 4593) Company Profile & Overview - Stock …
Dec 26, 2024 Company profile for Healios K.K. (TYO: 4593) with a description, list of executives, contact details and other key facts.See details»
Healios K.K. (HLOSF) Company Profile & Overview - Stock Analysis
Oct 9, 2024 The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is …See details»
HEALIOS K.K. Company Profile | CHIYODA-KU, TOKYO, Japan
Find company research, competitor information, contact details & financial data for HEALIOS K.K. of CHIYODA-KU, TOKYO. Get the latest business insights from Dun & Bradstreet.See details»
Healios K.K. (4593.T) Company Profile & Facts - Yahoo Finance
See the company profile for Healios K.K. (4593.T) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Company Healios K.K. - MarketScreener.com
Dec 31, 2012 Business description: Healios K.K. Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC …See details»
Healios KK - Overview, News & Similar companies | ZoomInfo.com
May 20, 2022 Who is Healios KK. Healios is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new …See details»
Healios K.K - VentureRadar
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid …See details»
HEALIOS Company Profile - Office Locations, Competitors ... - Craft
HEALIOS (株式会社ヘリオス) (formerly Retina Institute Japan) is a company engaged in research, development, and manufacturing of cell therapy and regenerative medicine …See details»
Healios Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Clinical Trials associated with Healios Co., Ltd. ISRCTN16270209 / Completed Not Applicable A randomised controlled trial of a conversational virtual avatar-led cognitive behavioural therapy …See details»
Healios KK, 4593:TYO profile - FT.com - Financial Times
Dec 30, 2024 Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which …See details»
HEALIOS CEO and key executive team | Craft.co
HEALIOS's Director is Seigo Kashii. Other executives include Yoshinari Matsuda, Director; Richard P. Kincaid, Executive Officer, CFO. Director and 2 others. See the full leadership team …See details»
Healios’ eNK Cells - QUICK Money World
Healios’ eNK Cells HEALIOS K.K. (“Healios”) is developing next-generation immuno-oncology therapies, with a focus on solid tumors, using NK cells*1 derived from allogeneic iPSCs …See details»
Healios KK, HLOSF:PKL profile - FT.com - Financial Times
6 days ago Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs).See details»
Healios Selected for the AMED Project to Promote the …
Dec 9, 2024 Healios is developing a dual CAR-eNK cell product, in which chimeric antigen receptors (CARs) that specifically recognize cancer antigens are introduced into the eNK to …See details»